JP2008508863A - フラビウイルス科ウイルスタンパク質発現のための組換えレンチウイルスベクター、及びワクチンとしてのそれらの使用 - Google Patents

フラビウイルス科ウイルスタンパク質発現のための組換えレンチウイルスベクター、及びワクチンとしてのそれらの使用 Download PDF

Info

Publication number
JP2008508863A
JP2008508863A JP2007517517A JP2007517517A JP2008508863A JP 2008508863 A JP2008508863 A JP 2008508863A JP 2007517517 A JP2007517517 A JP 2007517517A JP 2007517517 A JP2007517517 A JP 2007517517A JP 2008508863 A JP2008508863 A JP 2008508863A
Authority
JP
Japan
Prior art keywords
protein
virus
vector
flaviviridae
lentiviral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007517517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508863A5 (https=
Inventor
デスプレ，フィリップ
シャーニュー，ピエール
タンギー，フレデリク
フレンキエル，マリー−パスカル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2008508863A publication Critical patent/JP2008508863A/ja
Publication of JP2008508863A5 publication Critical patent/JP2008508863A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007517517A 2004-05-17 2005-05-16 フラビウイルス科ウイルスタンパク質発現のための組換えレンチウイルスベクター、及びワクチンとしてのそれらの使用 Pending JP2008508863A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
PCT/IB2005/001753 WO2005111221A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

Publications (2)

Publication Number Publication Date
JP2008508863A true JP2008508863A (ja) 2008-03-27
JP2008508863A5 JP2008508863A5 (https=) 2008-07-03

Family

ID=34945000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517517A Pending JP2008508863A (ja) 2004-05-17 2005-05-16 フラビウイルス科ウイルスタンパク質発現のための組換えレンチウイルスベクター、及びワクチンとしてのそれらの使用

Country Status (9)

Country Link
US (2) US20090214589A1 (https=)
EP (2) EP1751291B1 (https=)
JP (1) JP2008508863A (https=)
CN (1) CN1981043B (https=)
BR (1) BRPI0510016B8 (https=)
CA (1) CA2564934C (https=)
FR (1) FR2870126B1 (https=)
MX (1) MXPA06013388A (https=)
WO (1) WO2005111221A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535693A (ja) * 2010-08-12 2013-09-12 クロンテック・ラボラトリーズ・インコーポレーテッド 非診断用分析物のためのラテラルフローアッセイ
JP2017538417A (ja) * 2014-12-11 2017-12-28 アンスティテュ・パストゥール レンチウイルスベクターに基づく日本脳炎免疫原性組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
US20110262472A1 (en) * 2008-04-22 2011-10-27 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
WO2017083291A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
SG11202004234SA (en) 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512804A (ja) * 1998-04-24 2002-05-08 インスティチュート・パスツール ヌクレオチド配列の導入のためのトリプレックス構造のｄｎａ配列の利用
JP2003501661A (ja) * 1999-06-09 2003-01-14 インスティティ・パスツール Ｎｓ１糖タンパク質を用いるフラビウイルスの早期検出
JP2003511080A (ja) * 1999-10-11 2003-03-25 アンスティテュ・パストゥール 免疫治療組成物調製用のレンチウイルスベクター
US20030104611A1 (en) * 1998-01-16 2003-06-05 Johnston Julie C. Feline immunodeficiency virus gene therapy vectors
WO2004037846A1 (de) * 2002-10-24 2004-05-06 Christian Jassoy Immunisierung gegen bestandteile des humanen immunschwächevirus (hiv)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317509B1 (ko) * 1992-07-16 2002-02-20 야스모토 토루 C형간염바이러스를분류하기위한항원성펩티드,이펩티드를포함하는키트및이펩티드를사용하는c형간염바이러스를분류하는방법
US5883081A (en) 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
AU4554899A (en) 1998-06-09 1999-12-30 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
EP1092780A1 (en) 1999-10-13 2001-04-18 Boehringer Ingelheim International GmbH Recombiant, replication defective CELO virus and CELO virus DNA
CA2443290C (fr) 2001-04-04 2011-11-08 Institut Pasteur Souche neurovirulente du virus west-nile et ses applications
US20040037848A1 (en) 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
CA2903126C (en) 2002-01-10 2020-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
CA2456873A1 (en) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) West nile virus proteins and genes coding the foregoing and their use in vaccinal, therapeutic and diagnostic applications
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104611A1 (en) * 1998-01-16 2003-06-05 Johnston Julie C. Feline immunodeficiency virus gene therapy vectors
JP2002512804A (ja) * 1998-04-24 2002-05-08 インスティチュート・パスツール ヌクレオチド配列の導入のためのトリプレックス構造のｄｎａ配列の利用
JP2003501661A (ja) * 1999-06-09 2003-01-14 インスティティ・パスツール Ｎｓ１糖タンパク質を用いるフラビウイルスの早期検出
JP2003511080A (ja) * 1999-10-11 2003-03-25 アンスティテュ・パストゥール 免疫治療組成物調製用のレンチウイルスベクター
WO2004037846A1 (de) * 2002-10-24 2004-05-06 Christian Jassoy Immunisierung gegen bestandteile des humanen immunschwächevirus (hiv)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535693A (ja) * 2010-08-12 2013-09-12 クロンテック・ラボラトリーズ・インコーポレーテッド 非診断用分析物のためのラテラルフローアッセイ
US9945850B2 (en) 2010-08-12 2018-04-17 Takara Bio Usa, Inc. Lateral flow assays for non-diagnostic analytes
JP2017538417A (ja) * 2014-12-11 2017-12-28 アンスティテュ・パストゥール レンチウイルスベクターに基づく日本脳炎免疫原性組成物

Also Published As

Publication number Publication date
EP1751291B1 (en) 2013-07-31
BRPI0510016B1 (pt) 2020-03-10
CN1981043A (zh) 2007-06-13
US20090214589A1 (en) 2009-08-27
BRPI0510016A (pt) 2007-09-18
MXPA06013388A (es) 2007-06-19
CN1981043B (zh) 2010-06-09
WO2005111221A1 (en) 2005-11-24
CA2564934A1 (en) 2005-11-24
FR2870126A1 (fr) 2005-11-18
BRPI0510016B8 (pt) 2021-05-25
EP1751291A1 (en) 2007-02-14
EP2371966B1 (en) 2015-11-25
US8716013B2 (en) 2014-05-06
EP2371966A1 (en) 2011-10-05
US20110206710A1 (en) 2011-08-25
CA2564934C (en) 2014-07-08
FR2870126B1 (fr) 2009-07-17

Similar Documents

Publication Publication Date Title
US8716013B2 (en) Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
US8728488B2 (en) Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens
US10040824B2 (en) Flavivirus vaccine
US8158413B2 (en) Lentiviral vector-based vaccine
Brinton et al. Immune mediated and inherited defences against flaviviruses
US6455509B1 (en) Dengue nucleic acid vaccines that induce neutralizing antibodies
CN102711817B (zh) 基于dna疫苗和嵌合体病毒的诱导抗登革热病毒的免疫应答的方法、试剂盒、质粒和组合物
EP2020444B1 (en) Defective non-integrative lentiviral transfer vectors for vaccines
US8222029B2 (en) Lentiviral vector-based vaccine
Campos Evaluation of a Tetravalent DNA Vaccine against Dengue: Integrating Biochemical Studies on Dengue Virus Envelope Protein to a Domain-Based Antigen Design
Timpona VSV vectors as vaccines for emerging viruses and as probes for entry pathways
Zeng Mapping of four immunodominant epitopes of dengue virus-specific human CD4 (+) T cell clones and analysis of simian hemorrhagic fever virus RNAs
Widman Characterization of single-cycle flavivirus particles for use as a vaccine to prevent West Nile disease and to examine immune responses to flavivirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130129